Clinuvel Pharmaceuticals Ltd (ASX: CUV) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


Clinuvel Pharmaceuticals Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $750.17 million
P/E Ratio 26.35
Dividend Yield 0.33%
Shares Outstanding 50.10 million
Earnings per share 0.573
Dividend per share 0.05
Year To Date Return -5.63%
Earnings Yield 3.79%
Franking 100%
Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

  • Clinuvel Pharmaceuticals Ltd (ASX: CUV)
    Latest News

    A worried man holds his head and look at his computer.
    Share Fallers

    Why Clinuvel, Mesoblast, Red Hill, and Resimac shares are sinking today

    These shares are having a tough time on Tuesday. But why?

    Read more »

    a woman holds her hands to her temples as she sits in front of a computer screen with a concerned look on her face.
    Share Fallers

    Why Bowen Coking Coal, Clinuvel, Meteoric Resources, and Pilbara Minerals shares are falling

    These shares are starting the week in the red. But why?

    Read more »

    A young male ASX investor raises his clenched fists in excitement because of rising ASX share prices today
    Share Gainers

    Why Clinuvel, Guzman y Gomez, Magellan, and Sandfire shares are charging higher

    These shares are ending the week with a bang. But why?

    Read more »

    Shot of a young scientist using a digital tablet while working in a lab.
    Healthcare Shares

    Why is this ASX 300 healthcare stock surging 12% today?

    An announcement is getting investors excited today. Let's find out what's happening.

    Read more »

    A young man talks tech on his phone while looking at a laptop. A financial graph is superimposed across the image.
    Broker Notes

    Guess which ASX 300 share could rise over 50%

    Bell Potter sees huge upside for this buy-rated stock. Let's see why it is bullish.

    Read more »

    Smiling man with phone in wheelchair watching stocks and trends on computer
    Share Market News

    5 things to watch on the ASX 200 on Tuesday

    A better session is expected for Aussie investors today.

    Read more »

    Shot of a young scientist using a digital tablet while working in a lab.
    Healthcare Shares

    Which ASX biotech shares are pioneering the future of medicine?

    Uncover the risks and rewards of high-stakes investments in ASX biotech stocks.

    Read more »

    A young female investor sits in her home office looking at her ipad and smiling as she sees the QBE share price rising
    Broker Notes

    7 ASX All Ords shares elevated to 'strong buy' status in March

    There are blue chips and small caps on this list.

    Read more »

    Kid on a skateboard with cardboard wings soars along the road.
    How to invest

    Shares vs. property: Why cheaper homes and ASX small-cap shares are rising fastest in 2024

    We look into the changing trends in shares vs. property.

    Read more »

    A beautiful woman holds up one finger with one hand and has her hand on her waist with the other as she smiles widely as though she is very pleased about something.
    Share Gainers

    Why Beach, Clinuvel, Deep Yellow, and EML shares are charging higher today

    These ASX shares are ending the week strongly. But why?

    Read more »

    A man clenches his fists in excitement as gold coins fall from the sky.
    Share Gainers

    Why Arafura, Bubs, Clinuvel, and Superloop shares are racing higher today

    Why are investors getting excited about these shares today?

    Read more »

    Man with rocket wings which have flames coming out of them.
    Broker Notes

    These ASX shares could rise 30% to 50% in 12 months

    Big returns could be on the cards for owners of these shares according to analysts.

    Read more »

    Frequently Asked Questions

    Yes, Clinuvel Pharmaceuticals has historically paid one unfranked shareholder dividend a year.

    Clinuvel Pharmaceuticals generally pays its shareholder dividend in September.

    Clinuvel Pharmaceuticals does not have a dividend reinvestment plan.

    Clinuvel Pharmaceuticals Limited listed on the ASX on 13 February 2001.

    Dividend Payment History Data provided by Morningstar.

    Data provided by Morningstar.
    Ex-Date Amount Franking Type Payable
    05 Sep 2023 $0.0500 100.00% Final 20 Sep 2023
    06 Sep 2022 $0.0400 100.00% Final 21 Sep 2022
    02 Sep 2021 $0.0250 0.00% Final 17 Sep 2021
    03 Sep 2020 $0.0250 0.00% Final 18 Sep 2020
    04 Sep 2019 $0.0250 0.00% Final 19 Sep 2019
    21 Sep 2018 $0.0200 0.00% Final 08 Oct 2018

    CUV ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

    About Clinuvel Pharmaceuticals Ltd

    Clinuvel Pharmaceuticals Ltd (ASX: CUV) is an Australian-based global biopharmaceutical company developing drugs for the treatment of genetic and vascular disorders. Its principal product SCENESSE is a drug for an inherited disorder, erythropoietic protoporphyria, that causes an intolerance to light.

    Its pioneering work aims at preventing the symptoms of skin diseases related to exposure to UV radiation and at repigmentation of the skin due to depigmentation disorders. Geographically, the company derives the majority of its revenue from its US and European markets.


    CUV Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    25 Jul 2024 $14.98 $-0.12 -0.79% 24,323 $15.02 $15.13 $14.85
    24 Jul 2024 $15.10 $-0.10 -0.66% 47,380 $15.10 $15.28 $14.91
    23 Jul 2024 $15.20 $-0.05 -0.33% 28,221 $15.19 $15.46 $15.07
    22 Jul 2024 $15.25 $-0.28 -1.80% 32,853 $15.30 $15.59 $15.25
    19 Jul 2024 $15.53 $0.29 1.90% 56,022 $15.35 $15.55 $15.03
    18 Jul 2024 $15.24 $-0.12 -0.78% 39,997 $15.30 $15.55 $15.13
    17 Jul 2024 $15.36 $-0.08 -0.52% 37,545 $15.62 $15.63 $15.36
    16 Jul 2024 $15.44 $-0.18 -1.15% 48,476 $15.60 $15.75 $15.39
    15 Jul 2024 $15.62 $-0.03 -0.19% 56,750 $15.65 $15.88 $15.53
    12 Jul 2024 $15.65 $0.59 3.92% 62,661 $15.27 $15.65 $15.05
    11 Jul 2024 $15.06 $0.22 1.48% 87,019 $14.88 $15.27 $14.73
    10 Jul 2024 $14.84 $0.26 1.78% 91,967 $14.61 $14.99 $14.40
    09 Jul 2024 $14.58 $-0.93 -6.00% 285,103 $15.35 $15.74 $14.23
    08 Jul 2024 $15.51 $-1.87 -10.76% 180,146 $17.33 $17.35 $15.39
    05 Jul 2024 $17.38 $2.21 14.57% 346,972 $15.20 $17.71 $15.16
    04 Jul 2024 $15.17 $-0.08 -0.52% 50,940 $15.38 $15.56 $15.02
    03 Jul 2024 $15.25 $-0.01 -0.07% 27,240 $15.25 $15.32 $15.22
    02 Jul 2024 $15.26 $-0.01 -0.07% 15,721 $15.26 $15.45 $15.25
    01 Jul 2024 $15.27 $-0.10 -0.65% 43,338 $15.34 $15.35 $15.02
    28 Jun 2024 $15.37 $0.13 0.85% 82,639 $15.36 $15.54 $15.18
    27 Jun 2024 $15.24 $-0.14 -0.91% 116,576 $15.38 $15.45 $15.12
    26 Jun 2024 $15.38 $-0.32 -2.04% 82,968 $15.69 $15.89 $15.25
    25 Jun 2024 $15.70 $0.47 3.09% 116,452 $15.45 $15.75 $15.18

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    24 Nov 2023 Philippe Wolgen Transfer 3,124,097 $53,109,649
    Off-market transfer. Assuming off market transfer of shares
    24 Nov 2023 Philippe Wolgen Transfer 3,124,097 $53,109,649
    Off-market transfer. Assuming off market transfer of shares
    24 Nov 2023 Philippe Wolgen Buy 301,125 $5,119,125
    Conversion of securities.
    24 Nov 2023 Philippe Wolgen Exercise 301,125 $5,119,125
    Conversion of securities.
    24 Nov 2023 Philippe Wolgen Expiry 1,212,625 $20,614,625
    As advised by the company. Lapsed, 3,01,125 Rights
    19 Sep 2023 Philippe Wolgen Buy 1,850 $29,813
    On-market trade.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Ms Brenda Mary Shanahan Non-Executive Director Dec 2007
    Mrs Shanahan has more tha 20 year's of experience in medical R&D and commercialisation. She is currently a non executive director of Phoslock Water Solutions Ltd
    Mrs Susan (Sue) Smith Non-Executive Director Sep 2019
    Mrs Smith is the Chief Executive Officer of the Independent Doctors Federation, a membership organisation representing practicing physicians within the UK independent healthcare sector. Mrs Smith also manages a consultancy business, providing advisory services to a range of healthcare organisations, investors and boards of directors. Prior to her current roles Mrs Smith has a career, serving for 14 years as Chief Executive Officer of The Princess Grace Hospital, London, and 11 years as the Chief Executive Officer of The Portland Hospital for Women and Children, London. Based in London, Mrs Smith is also Non-Executive Board Chair of Women's Health (London West One) Ltd, a specialist medical practice, Non-Executive Director of Elite Medicine Ltd, a precision medicine company, and a Trustee of the HCA International Foundation.
    Dr Philippe J Wolgen Chief Executive OfficerManaging Director Dec 2005
    Dr Wolgen is currently leading the Group's expansion, with an immediate focus on the US and the further development of the product pipeline for various market segments. His focus has been to establish a professional management team to execute the corporate objectives set and prepare next generation of managers.
    Dr Karen Agersborg Non-Executive Director Jan 2018
    Dr Agersborg had previously worked at Reading Hospital, West Reading and at Suburban Hospital, Norristown as Clinical Endocrinologist and served as Chief, Endocrinology, Diabetes, Metabolism at Chestnut Hill Hospital. Dr Agersborg had a career in managing commercial sales & distribution at Wyeth Pharmaceuticals (formerly Ayerst Laboratories). Dr Agersborg is also integral to setting US commercial strategy, pending US approval of SCENESSE, a decision on an approval expected later in 2019.
    Dr Jeffrey Rosenfeld Non-Executive ChairmanNon-Executive Director Nov 2019
    Dr Rosenfeld has experience in senior healthcare and research executive roles and career in the Australian Army Reserve. He was the Founding Director of Monash University Institute of Medical Engineering (MIME-Melbourne) and acted as Board Chair for the Security and Health Executive Leadership Institute at The University of Melbourne. For 15 years Dr Rosenfeld was Director of Neurosurgery at the Alfred Hospital, concurrently holding for nine years the position of Professor and Head of the Department of Surgery at Monash University. Dr Rosenfeld is an active member of the Melbourne community and is involved in various charitable causes. He has devoted much of his time to the Australian-Aid funded Pacific Islands Project for transfer of clinical skills and knowhow to healthcare professionals in Papua New Guinea, Fiji and the Solomon Islands. One of Australia's senior and experienced military surgeons, Dr Rosenfeld served on eight deployments to Rwanda, Bougainville, East Timor, the Solomon Islands and Iraq. Having attained the rank of Major General, Dr Rosenfeld is also a former Surgeon General of the Australian Defence Force and remains active in defence and veterans' affairs organisations.In 2018, he received the International Lifetime Recognition Award of the American Association of Neurological Surgeons.
    Dr Emilie Rodenburger Non-Executive Director Apr 2024
    Dr Rodenburger previously worked with the CLINUVEL Group for over a decade in clinical development roles in Australia, the USA and Europe. Dr Rodenburger spent four years with Roche in senior clinical roles. Based in the UK, Dr Rodenburger will oversee CLINUVEL global clinical program.
    Dr Peter Vaughan Company Secretary Jun 2024
    Peter Vaughan Company Secretary

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    HSBC Custody Nominees (Australia) Ltd 11,280,990 22.83%
    BNP Paribas Nominees Pty Ltd Acf Clearstream 5,679,762 11.50%
    BNP Paribas Nominees Pty Ltd 5,312,764 10.75%
    J P Morgan Nominees Australia Pty Ltd 4,390,776 8.89%
    Dr Philippe Jacques Wolgen 3,122,247 6.32%
    Citicorp Nominees Pty Ltd 3,014,759 6.10%
    Ender 1 LLC 2,590,824 5.24%
    BNP Paribas Nominees Pty Ltd (ii) 1,482,356 3.00%
    Emilino Group Pty Ltd 603,447 1.22%
    National Nominees Ltd 548,371 1.11%
    Dr Mark Edwin Badcock 440,085 0.89%
    Mr David William Trevorrow 229,600 0.46%
    Mr David John Lewis 187,000 0.38%
    HSBC Custody Nominees (Australia) Ltd a/c 2 180,199 0.36%
    Mr Trent Sheldon Redding 179,480 0.36%
    Mr Darren Michael Keamy 178,588 0.36%
    Rusty Hammer Pty Ltd 156,892 0.32%
    Dr Dennis Wright 156,874 0.32%
    Mr Simon John Bown 146,000 0.30%
    BNP Paribas Noms (NZ) Ltd 130,710 0.26%